Susan Gorschboth
Primary Care · Abingdon, MDNPI 1639722036
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$551
- AstraZeneca$459
- GSK$316
- AbbVie$306
- Lilly USA, LLC$284
- Astellas Pharma US Inc$229
- plus $828 from 16 others
What the payments were for
- Food & beverage$2,973100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 39 | $551 |
| AstraZeneca(2 entities) | 14 | $459 |
| GSK | 15 | $316 |
| AbbVie | 22 | $306 |
| Lilly USA, LLC | 16 | $284 |
| Astellas Pharma US Inc | 11 | $229 |
| Exact Sciences | 7 | $171 |
| Pfizer | 8 | $167 |
| Amgen | 6 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $84 |
| Dexcom, Inc. | 2 | $44 |
| Bayer | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Merck | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Abbott | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,973 in reported general payments places this provider in the 90th percentile of 191 primary care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $95,948 |
| OzempicSemaglutide | 55 | $95,136 |
| JanuviaSitagliptin Phosphate | 55 | $57,520 |
| EliquisApixaban | 40 | $45,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $39,678 |
| MounjaroTirzepatide | 14 | $18,887 |
| Atorvastatin Calcium | 447 | $6,123 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $3,217 |
| Rosuvastatin Calcium | 116 | $2,901 |
| Duloxetine Hcl | 78 | $2,479 |
| Metoprolol Succinate | 119 | $2,430 |
| Lisinopril | 253 | $2,166 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $2,138 |
| Levothyroxine Sodium | 184 | $1,976 |
| Gabapentin | 93 | $1,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $551 | $95,13655 claims |
| MerckJanuvia | $27 | $57,52055 claims |
| PfizerEliquis | $167 | $45,77740 claims |
| GSKTrelegy Ellipta | $316 | $39,67838 claims |
| Lilly USA, LLCMounjaro | $284 | $18,88714 claims |
| AbbVieSynthroid | $306 | $1,09515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 primary care providers in Maryland.
Other primary care in Abingdon
- Ashley SalamoneBaltimore$13K
- Ololade IkuomolaBaltimore$10K
- Patricia GoodmanUppr Marlboro$8K
- Jody LeonardAnnapolis$7K
- Yury MalachevskyBaltimore$7K
- Kyleen DavisChevy Chase$6K
- Laura Ferguson-WeigmanBel Air$5K
- Roza LissGaithersburg$5K
- Anita Tuli-KendallGaithersburg$5K
- Hannah WhiteheadEssex$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.